Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

The aim of the study was to evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP) in combination with standard therapy in patients with acute decompensated heart failure (ADHF).

Bibliographic Details
Main Authors: Wang, Guogan, Wang, Pengbo, Li, Yishi, Liu, Wenxian, Bai, Shugong, Zhen, Yang, Li, Dongye, Yang, Ping, Chen, Yu, Hong, Lang, Sun, Jianhui, Chen, Junzhu, Wang, Xian, Zhu, Jihong, Hu, Dayi, Li, Huimin, Wu, Tongguo, Huang, Jie, Tan, Huiqiong, Zhang, Jian, Liao, Zhongkai, Yu, Litian, Mao, Yi, Ye, Shaodong, Feng, Lei, Hua, Yihong, Ni, Xinhai, Zhang, Yuhui, Wang, Yang, Li, Wei, Luan, Xiaojun, Sun, Xiaolu, Wang, Sijia
Format: Online
Language:English
Published: Wolters Kluwer Health 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782891/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782891/

Similar Items